Literature DB >> 7530865

Iron(II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum.

E Kim1, S N Giri, I N Pessah.   

Abstract

Iron is examined for its ability to modify Ca2+ transport across sarcoplasmic reticulum (SR) and to alter the binding of [3H]ryanodine to its high-affinity site on the Ca2+ release channel complex of SR preparations from rat heart. Iron(III) (added as ferric chloride) has negligible activity on active Ca2+ accumulation into SR and on the binding of [3H]ryanodine. In contrast, Fe(II) (added as ferrous sulfate) is a potent inhibitor of both Ca(2+)-induced Ca2+ release (IC50 of 29 microM) and DXR-induced Ca2+ release (IC50 of 14 microM). Iron(II) enhances the rate of active Ca2+ uptake into SR vesicles, mimicking the actions of the known SR Ca2+ channel blocker ruthenium red. The underlying mechanism of Fe(II) on SR Ca2+ transport is shown to be a direct and potent action on the ryanodine receptor. Fe(II) inhibits the binding of [3H]ryanodine when assayed in the presence of 5 microM Ca2+ with an IC50 of 4 microM and in an apparently cooperative manner (nH = 1.7). In the presence of physiological (1 mM) Mg2+, Fe(II) decreases the sensitivity of ryanodine receptors toward activation by Ca2+ shifting EC50 from 18 to 35 microM in the absence and presence of 5 microM Fe(II), respectively, without significant decrease in maximum [3H]ryanodine occupancy. In the presence of 5 microM Ca2+ and 1 mM Mg2+, Fe(II) decreases the potency of doxorubicin (DXR) on [3H]ryanodine binding (shifts EC50 from 8 to 24 microM in the absence and presence of 5 microM Fe(II)). These results suggest that Fe(II) competes with Ca2+ at the activator sites on the channel complex. The actions of Fe(II) on ryanodine receptor function is not correlated with membrane lipid peroxidation of SR vesicles since Fe(II) does not produce detectable changes in malondialdehyde using the thiobarbituric acid assay. These results demonstrate a direct inhibition of the Ca2+ release channel of cardiac SR by Fe(II) which may be important in pathological states of the heart during iron overload.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7530865     DOI: 10.1006/taap.1995.1008

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  19 in total

Review 1.  Electrocardiographic Presentation, Cardiac Arrhythmias, and Their Management in β-Thalassemia Major Patients.

Authors:  Vincenzo Russo; Anna Rago; Andrea Antonio Papa; Gerardo Nigro
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-06-20       Impact factor: 1.468

2.  Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.

Authors:  John C Wood; Maya Otto-Duessel; Ignacio Gonzalez; Michelle I Aguilar; Hiro Shimada; Hanspeter Nick; Marvin Nelson; Rex Moats
Journal:  Transl Res       Date:  2006-11       Impact factor: 7.012

3.  Fe²⁺ block and permeation of CaV3.1 (α1G) T-type calcium channels: candidate mechanism for non-transferrin-mediated Fe²⁺ influx.

Authors:  Kyle V Lopin; I Patrick Gray; Carlos A Obejero-Paz; Frank Thévenod; Stephen W Jones
Journal:  Mol Pharmacol       Date:  2012-09-12       Impact factor: 4.436

Review 4.  Physiology and pathophysiology of iron cardiomyopathy in thalassemia.

Authors:  John C Wood; Cathleen Enriquez; Nilesh Ghugre; Maya Otto-Duessel; Michelle Aguilar; Marvin D Nelson; Rex Moats; Thomas D Coates
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

Review 5.  Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy: an update.

Authors:  Richard Gordan; Suwakon Wongjaikam; Judith K Gwathmey; Nipon Chattipakorn; Siriporn C Chattipakorn; Lai-Hua Xie
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

6.  Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat.

Authors:  B E Burke; H Gambliel; R D Olson; F K Bauer; B J Cusack
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

7.  Ventriculo-vascular interactions in patients with beta thalassaemia major.

Authors:  Y F Cheung; S Y Ha; G C F Chan
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

Review 8.  Iron overload thalassemic cardiomyopathy: iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity.

Authors:  Suree Lekawanvijit; Nipon Chattipakorn
Journal:  Can J Cardiol       Date:  2009-04       Impact factor: 5.223

9.  Iron overload decreases CaV1.3-dependent L-type Ca2+ currents leading to bradycardia, altered electrical conduction, and atrial fibrillation.

Authors:  Robert A Rose; Michael Sellan; Jeremy A Simpson; Farzad Izaddoustdar; Carlo Cifelli; Brian K Panama; Mark Davis; Dongling Zhao; Moniba Markhani; Geoffrey G Murphy; Joerg Striessnig; Peter P Liu; Scott P Heximer; Peter H Backx
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-07-11

10.  Dynamic dyssynchrony and impaired contractile reserve of the left ventricle in beta-thalassaemia major: an exercise echocardiographic study.

Authors:  Yiu-fai Cheung; Wei Yu; Shu-na Li; Wendy W M Lam; Yuen-chi Ho; Sophia J Wong; Godfrey C F Chan; Shau-yin Ha
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.